News Releases

Myeloid Therapeutics to Participate at Upcoming Investor Conferences

CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences:

Chardan's 7^th Annual Genetic Medicines Conference, taking place October 2-3, 2023, in NY
Oppenheimer's Private Company Symposium, taking place October 11, 2023, in NY
3^rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023

About Myeloid Therapeutics

Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer. Integrating the fields of RNA, immunology and medicine, the Company's proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, and RNA-based gene-editing using RetroT^™.

Investor and Media Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
858-914-1962

SOURCE Myeloid Therapeutics